Literature DB >> 25420002

Treating hearing disorders with cell and gene therapy.

Lisa N Gillespie, Rachael T Richardson, Bryony A Nayagam, Andrew K Wise.   

Abstract

Hearing loss is an increasing problem for a substantial number of people and, with an aging population, the incidence and severity of hearing loss will become more significant over time. There are very few therapies currently available to treat hearing loss, and so the development of new therapeutic strategies for hearing impaired individuals is of paramount importance to address this unmet clinical need. Most forms of hearing loss are progressive in nature and therefore an opportunity exists to develop novel therapeutic approaches to slow or halt hearing loss progression, or even repair or replace lost hearing function. Numerous emerging technologies have potential as therapeutic options. This paper details the potential of cell- and gene-based therapies to provide therapeutic agents to protect sensory and neural cells from various insults known to cause hearing loss; explores the potential of replacing lost sensory and nerve cells using gene and stem cell therapy; and describes the considerations for clinical translation and the challenges that need to be overcome.

Entities:  

Mesh:

Year:  2014        PMID: 25420002     DOI: 10.1088/1741-2560/11/6/065001

Source DB:  PubMed          Journal:  J Neural Eng        ISSN: 1741-2552            Impact factor:   5.379


  8 in total

1.  It's All in the Delivery: Improving AAV Transfection Efficiency with Exosomes.

Authors:  Donna M Martin; Yehoash Raphael
Journal:  Mol Ther       Date:  2017-01-23       Impact factor: 11.454

Review 2.  [Intracochlear drug delivery in combination with cochlear implants : Current aspects].

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2016-11       Impact factor: 1.284

Review 3.  Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications.

Authors:  Alec N Salt; Stefan K Plontke
Journal:  Hear Res       Date:  2018-03-11       Impact factor: 3.208

4.  Methionine Sulfoxide Reductase B3-Targeted In Utero Gene Therapy Rescues Hearing Function in a Mouse Model of Congenital Sensorineural Hearing Loss.

Authors:  Min-A Kim; Hyun-Ju Cho; Seung-Hyun Bae; Byeonghyeon Lee; Se-Kyung Oh; Tae-Jun Kwon; Zae-Young Ryoo; Hwa-Young Kim; Jin-Ho Cho; Un-Kyung Kim; Kyu-Yup Lee
Journal:  Antioxid Redox Signal       Date:  2016-01-21       Impact factor: 8.401

Review 5.  Intracochlear drug delivery in combination with cochlear implants : Current aspects.

Authors:  S K Plontke; G Götze; T Rahne; A Liebau
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

Review 6.  Reprogramming Glia Into Neurons in the Peripheral Auditory System as a Solution for Sensorineural Hearing Loss: Lessons From the Central Nervous System.

Authors:  Steven J Meas; Chun-Li Zhang; Alain Dabdoub
Journal:  Front Mol Neurosci       Date:  2018-03-14       Impact factor: 5.639

7.  Alginate-encapsulated brain-derived neurotrophic factor-overexpressing mesenchymal stem cells are a promising drug delivery system for protection of auditory neurons.

Authors:  Jana Schwieger; Anika Hamm; Michael M Gepp; André Schulz; Andrea Hoffmann; Thomas Lenarz; Verena Scheper
Journal:  J Tissue Eng       Date:  2020-04-17       Impact factor: 7.813

8.  Viral-mediated Ntf3 overexpression disrupts innervation and hearing in nondeafened guinea pig cochleae.

Authors:  Min Young Lee; Takaomi Kurioka; Megan M Nelson; Diane M Prieskorn; Donald L Swiderski; Yohei Takada; Lisa A Beyer; Yehoash Raphael
Journal:  Mol Ther Methods Clin Dev       Date:  2016-08-03       Impact factor: 6.698

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.